Fig. 2: Monoclonal antibodies against NL63 spike.
From: Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus
a Organisation of the NL63 spike protein. Upper part: linear depiction of NL63 spike genome (not to scale). The S1 subunit consists of domains 0, A, B, C and D. Lower part: cryo-ET structure of the trimeric NL63 spike (PDB: 8FR7) with the subdomains of one protomer shown in coloured ribbons. The other two protomers are shown in grey. b Germline identity and CDR3 sequences of 9 NL63 spike-specific human mAbs. c Binding and neutralisation specificity of NL63 mAbs. Binding of mAbs was assessed via ELISA against full length spike and subdomains S1B, S10, S10 + S1A from NL63. Breadth was assessed against spike proteins from the ChinaGD02 NL63 strain, 229E, SADS-CoV (swine acute diarrhoea syndrome coronavirus) and SARS-CoV-2. Receptor binding inhibition was assessed via a S1B (RBD)-ACE2 inhibition ELISA while neutralisation was assessed using live NL63 virus isolates (Amsterdam1 and contemporary isolates) in HAT24 cells. ELISA binding and neutralisation titration curves are provided in Supplementary Fig. 2 and 4. Dashes indicate no binding or neutralising activity. The receptor binding inhibition ELISA and neutralisation assays were performed in duplicate and are representative data from single experiments.
